Development Hormones Radiology 
Worldwide Clinical Trials
JULY 8, 2024
With radiopharmaceuticals emerging as a diagnostic and therapeutic (theranostics) procedure, many are in the clinical development pipeline and are expected to play a crucial role in the future of healthcare. Pregnancy : Radiation exposure during pregnancy can potentially harm the developing fetus.
The Pharma Data
FEBRUARY 21, 2022
At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
SEPTEMBER 27, 2021
It can be due to the previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or on the basis of etiology that is characterized by a lack of previous signs of brain damage. Further, more than 50% of the patients develop long-term neurologic deficits.
Delveinsight
DECEMBER 29, 2020
Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist.
The Pharma Data
AUGUST 15, 2021
Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. The major efficacy endpoint for the treatment of VHL-associated RCC was ORR measured by radiology assessment using RECIST v1.1 months (range, 2.8 as assessed by IRC. Lactation.
pharmaphorum
MARCH 11, 2021
Across the UK, radiology departments are understaffed by around 43%, while only 3% of histopathology departments have enough staff to meet clinical demand. The theoretical value of this to a patient’s health, longevity and quality of life is enormous.
The Pharma Data
MARCH 17, 2021
In adjuvant breast cancer trials, this includes the length of time before any cancer comes back, a new cancer develops or death. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia. Two deaths due to neutropenic sepsis were observed in MONARCH 2.
Expert insights. Personalized for you.
130 
Let's personalize your content